Eris to buy Strides' India generic drug business for â¹500 cr
Ahmedabad-based drugmaker Eris Lifesciences signed an agreement with Bengaluru-based Strides Shasun to acquire its India branded generics business for â¹500 crore. Eris Lifesciences will acquire over 130 brands in the domains of neurology, psychiatry, and gastro, among others, along with employees who form part of the business. The acquired drugs had sales of â¹181 crore in 2016-17.